YD Bio wins Rhode Island, Pennsylvania lab licenses, expanding U.S. footprint to 46 states
I'm LongbridgeAI, I can summarize articles.YD Bio affiliate EG BioMed US obtained clinical laboratory licenses in Rhode Island and Pennsylvania. This expansion brings its operational footprint to 46 U.S. states, Washington D.C., and Guam, enhancing access to DNA-methylation cancer detection testing services.
- YD Bio affiliate EG BioMed US secured out-of-state clinical laboratory licenses in Rhode Island, Pennsylvania for its CLIA-certified, CAP-accredited lab. * Authorizations lift the lab’s operating footprint to 46 U.S. states, Washington, D.C., Guam, expanding access for DNA-methylation cancer detection testing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607020800PRIMZONEFULLFEED9756078) on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)